The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
Abstract
CONTEXT: Short-term data on the immunogenicity of monoclonal antibodies showed associations between the development of antidrug antibodies and diminished serum drug levels, and a diminished treatment response. Little is known about the clinical relevance of antidrug antibodies against these drugs during long-term follow-up. OBJECTIVE: To examine the course of antidrug antibody formation against fully human monoclonal antibody adalimumab and its clinical relevance during long-term (3-year) follow-up of patients with rheumatoid arthritis (RA). DESIGN, SETTING, AND PATIENTS: Prospective cohort study February 2004-September 2008; end of follow-up was September 2010. All 272 patients were diagnosed with RA and started treatment with adalimumab in an outpatient clinic. MAIN OUTCOME MEASURES: Disease activity was monitored and trough serum samples were obtained at baseline and 8 time points to 156 weeks. Serum adalimumab concentrations and antiadalimumab antibody titers were determined after follow-up. Treatment discontinuation, minimal disease activity, and clinical remission were compared for patients with and without antiadalimumab antibodies. RESULTS: After 3 years, 76 of 272 patients (28%) developed antiadalimumab antibodies--51 of these (67%) during the first 28 weeks of treatment. Patients without antiadalimumab antibodies had much higher adalimumab concentrations (median, 12 mg/L; IQR, 9-16 mg/L) compared with patients with antibody titers from 13 to 100 AU/mL (median, 5 mg/L; IQR, 3-9 mg/L; regression coefficient, -4.5; 95% CI, -6.0 to -2.9; P < .001) and also those greater than 100 AU/mL (median, 0 mg/L; IQR, 0-3 mg/L; regression coefficient, -7.1; 95% CI, -8.4 to -5.8; P < .001). Patients with antiadalimumab antibodies more often discontinued participation due to treatment failure (n = 29 [38%]; hazard ratio [HR], 3.0; 95% CI, 1.6-5.5; P < .001) compared with antiadalimumab antibody-negative ones (n = 28 [14%]). Ninety-five of 196 patients (48%) without antiadalimumab antibodies had minimal disease activity vs 10 of 76 patients (13%) with antiadalimumab antibodies; patients with antiadalimumab antibodies less often had sustained minimal disease activity score in 28 joints (DAS28) (< 3.2; HR, 3.6; 95% CI, 1.8-7.2; P < .001) compared with antiadalimumab antibody-negative ones. Three of 76 patients (4%) with antiadalimumab antibodies achieved sustained remission compared with 67 of 196 (34%) antiadalimumab antibody-negative ones; patients with antiadalimumab antibodies less often achieved remission (DAS28 < 2.6; HR, 7.1; 95% CI, 2.1-23.4; P < .001) compared with antiadalimumab antibody-negative ones. CONCLUSION: Among outpatients with RA in whom adalimumab was started over 3 years, the development of antidrug antibodies was associated with lower adalimumab concentration and lower likelihood of minimal disease activity or clinical remission.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevoo, M. L. L., Van'T Hof, M. A., Kuper, H. H., Van Leeuwen, M. A., Van De Putte, L. B. A., & Van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,243
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Vermeire, S., Noman, M., Van Assche, G., Baert, F., D’Haens, G., & Rutgeerts, P. (2007) · Gut · doi:10.1136/gut.2006.099978 · Cited by 602
Bartelds, G. M., Wijbrandts, C. A., Nurmohamed, M. T., Stapel, S., Lems, W. F., Aarden, L., Dijkmans, B. A. C., Tak, P. P., & Wolbink, G. J. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.065615 · Cited by 562
Self-citationKarmiris, K., Paintaud, G., Noman, M., Magdelaine–Beuzelin, C., Ferrante, M., Degenne, D., Claes, K., Coopman, T., Van Schuerbeek, N., Van Assche, G., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.07.062 · Cited by 478
Wolbink, G. J., Vis, M., Lems, W., Voskuyl, A. E., De Groot, E., Nurmohamed, M. T., Stapel, S., Tak, P. P., Aarden, L., & Dijkmans, B. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21671 · Cited by 471
Bendtzen, K., Geborek, P., Svenson, M., Larsson, L., Kapetanovic, M. C., & Saxne, T. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22214 · Cited by 384
Radstake, T. R. D. J., Svenson, M., Eijsbouts, A. M., van den Hoogen, F. H. J., Enevold, C., van Riel, P. L. C. M., & Bendtzen, K. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092833 · Cited by 377
The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL
Calabresi, P. A., Giovannoni, G., Confavreux, C., Galetta, S. L., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., O'Connor, P. W., Phillips, J. T., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000277457.17420.b5 · Cited by 339
Allez, M., Karmiris, K., Louis, E., Van Assche, G., Ben-Horin, S., Klein, A., Van der Woude, J., Baert, F., Eliakim, R., Katsanos, K., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2010.04.004 · Cited by 334
Bartelds, G. M., Wijbrandts, C. A., Nurmohamed, M. T., Stapel, S., Lems, W. F., Aarden, L., Dijkmans, B. A. C., Tak, P. P., & Wolbink, G. J. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.112847 · Cited by 225
Self-citationWolbink, G. J., Voskuyl, A. E., Lems, W. F., de Groot, E., Nurmohamed, M. T., Tak, P. P., Dijkmans, B. A. C., & Aarden, L. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.030452 · Cited by 215
Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease
WEST, R. L., ZELINKOVA, Z., WOLBINK, G. J., KUIPERS, E. J., STOKKERS, P. C. F., & VAN DER WOUDE, C. J. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03828.x · Cited by 213
Jamnitski, A., Bartelds, G. M., Nurmohamed, M. T., van Schouwenburg, P. A., van Schaardenburg, D., Stapel, S. O., Dijkmans, B. A. C., Aarden, L., & Wolbink, G. J. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.135111 · Cited by 178
Self-citationvan Schouwenburg, P. A., Bartelds, G. M., Hart, M. H., Aarden, L., Wolbink, G. J., & Wouters, D. (2010) · Journal of Immunological Methods · doi:10.1016/j.jim.2010.09.005 · Cited by 163
Self-citationUpdated consensus statement on biological agents for the treatment of rheumatic diseases, 2007
Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Burmester, G. R., Sieper, J., Emery, P., Keystone, E., Schiff, M., Mease, P. J., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.081430 · Cited by 153
Lecluse, L. L. A., Driessen, R. J. B., Spuls, P. I., de Jong, E. M. G. J., Stapel, S. O., van Doorn, M. B. A., Bos, J. D., & Wolbink, G. (2010) · Archives of Dermatology · doi:10.1001/archdermatol.2009.347 · Cited by 148
Miyasaka, N., & The CHANGE Study Investigators (2008) · Modern Rheumatology · doi:10.1007/s10165-008-0045-0 · Cited by 144
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease
Su, C. G., & Lichtenstein, G. R. (2003) · Gastroenterology · doi:10.1016/j.gastro.2003.05.009 · Cited by 104
Bartelds, G. M., de Groot, E. R., Nurmohamed, M. T., Hart, M. H. L., van Eede, P. H., Wijbrandts, C. A., Crusius, J. B. A., Dijkmans, B. A. C., Tak, P. P., Aarden, L. A., et al. (2010) · Arthritis Research & Therapy · doi:10.1186/ar3208 · Cited by 71
Self-citationBlom, M., Kievit, W., Kuper, H. H., Jansen, T., VISSER, H. K. A., den Broeder, A. A., Brus, H. L. M., van de Laar, M. A. F. J., & van Riel, P. L. C. M. (2010) · Arthritis Care & Research · doi:10.1002/acr.20211 · Cited by 37
Cited by
Methotrexate mechanism in treatment of rheumatoid arthritis
Friedman, B., & Cronstein, B. (2019) · Joint Bone Spine · doi:10.1016/j.jbspin.2018.07.004 · Cited by 439
Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
van Schouwenburg, P. A., Rispens, T., & Wolbink, G. J. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.4 · Cited by 438
Garcês, S., Demengeot, J., & Benito-Garcia, E. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202220 · Cited by 411
Plant-derived immunomodulators: an insight on their preclinical evaluation and clinical trials
Jantan, I., Ahmad, W., & Bukhari, S. N. A. (2015) · Frontiers in Plant Science · doi:10.3389/fpls.2015.00655 · Cited by 409
Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
Liu, L. (2018) · Protein & Cell · doi:10.1007/s13238-017-0408-4 · Cited by 390
Metadata
- Authors
- Bartelds, G. M.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2011-04-13
- Volume
- 305
- Issue
- 14
- Pages
- 1460
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2149065814
- Cited by
- 782
- References
- 22
- FWCI
- 23.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.